Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate
Crescent Biopharma Inc CBIO
$14.47
▼ -3.66%
($-0.55)
🔥 High Short Interest
Open
$15.14
Prev Close
$15.02
Day Range
$13.99 – $15.14
52W Range
$8.72 – $27.41
Market Cap
$534.81M
Beta
1.24
EPS (TTM)
$-12.33
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-01-10 |
| Shares Out. | 35,670,000 |
| Website | crescentbiopharma.com/ ↗ |
| Phone | 16174305595 |
| Employees | 44 |
| Net Income | -$24.8M |
| Free Cash Flow | -$73.6M |
| Total Assets | $182.8M |
| Total Liabilities | $19.5M |
| Equity | $163.3M |
About Crescent Biopharma Inc
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Crescent Biopharma Inc is a publicly traded company under the ticker symbol CBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)